MC Healthcare Ventures — Full Portfolio

miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.

BiotechBoulder, US

William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in

Co-investorsBRBrace PharmaBRBroadview VenturesRIRidgeback CapitalATAtlas VentureBOBoulder VenturesHEHeartland+1 more

Silence Therapeutics is a biotechnology company that discovers and develops short interfering RNA (siRNA) molecules designed to reduce the production of disease-associated proteins through the natural mechanism of RNA interference, with its proprietary mRNAi GOLD platform targeting specific genes in the liver for rare and common diseases.

BiotechLondon

Craig Tooman(Executive Officer)inGiles Campion(Executive Officer)Mark Rothera(Executive Officer, Director)inBarbara Ruskin(Executive Officer)

BoardJames Ede-Golightly(Director)Alistair Gray(Director)

Co-investorsFOForesite CapitalNENextech InvestVIVivo Capital

A venture studio embedded within Alloy Therapeutics that partners with academics, entrepreneurs, pharma companies, and VCs to create and develop early-stage drug discovery companies.

BiotechDeep TechWaltham, US

EBErrik B. Anderson(Executive Officer, Director)inPBPiotr Bobrowicz(Executive Officer, Director)inJay Rosanelli(Executive Officer)in

BoardAnthony Sun(Director)UNUlrik Nielsen(Director)in

Board seatAlaa Halawa· per SEC Form D · $40M raise · filed Apr 2026

Co-investors8282VS8V8VCALAlumni VenturesGEGermin8 VenturesJIJIC Venture Growth InvestmentsPRPresight Capital+2 more

Innovaccer offers Provider Copilot, an AI assistant that automates clinical documentation, pre-visit prep, medical scribing, and prior authorization workflows for healthcare providers and care teams.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechSan Francisco, US

ASAbhinav Shashank(Founder)inSGSandeep Gupta(Founder)inKHKanav Hasija(Founder)inWRWendy Rubas(Chief Legal and Compliance Officer of the Issuer)inSBScott Bruckner(Chief Financial Officer of the Issuer)AMAnkit Maheshwari(Chief Technology Officer of the Issuer)in

Board seatAlaa Halawa· per SEC Form D · filed Oct 2025

Co-investors50500 GlobalB B Capital GroupB4B4 CapitalLILightspeed India PartnersLILightspeed Venture PartnersM1M12 (Microsoft's Venture Fund)+9 more

Blacksmith Medicines discovers and develops small molecule inhibitors of metal-dependent enzymes for oncology and infectious disease applications.

BiotechDeep TechMedical Devices

Zachary Zimmerman(CEO)in

Capsigen engineers customized AAV (adeno-associated virus) capsids using its proprietary Transcription-Dependent Directed Evolution (TRADE) screening platform and data science to deliver gene therapies to specific target cells.

AI & Machine LearningBiotechHealthtechVancouver, US

JJohn(Chief Executive Officer)inCCharlie(Chief Business Officer)in

Draupnir Bio develops targeted protein degradation therapies using sortilin-based lysosome targeting chimeras to clear extracellular and membrane-bound protein aggregates in proteinopathies.

BiotechDeep TechMedical DevicesCopenhagen, DK

SGSimon Glerup(Professor)inCamilla Gustafsen(Professor)inPeder Søndergaard Madsen(Professor)Peter Seeberger(Professor)

Co-investorsINInkefGIGilde HealthcareNONovo Holdings

Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.

BiotechSan Carlos, US

HYHugh Y. Rienhoff, Jr., M.D.(Executive Officer, Director)in

BoardMSMarten Steen(Director)inDennis Henner, Ph.D.(Director)Bryant E. Fong(Director)

Co-investorsHEHealthCapCLClarus Ventures

Forge Therapeutics operates a drug discovery platform focused on developing medicines that target human metalloenzymes.

BiotechDeep Tech

Co-investorsALAlexandria

Genkyotex was a developer of NOX inhibitor therapeutics, now owned by Calliditas Therapeutics AB.

Biotech

Co-investorsANAndera PartnersVEVesalius Biocapital Partners

Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.

BiotechCambridge, US

Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)inMichael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)

Co-investorsCYCycad Group LLCLULux CapitalADAdvent Life SciencesALAlexandriaAUAuriga PartnersBIBill & Melinda Gates Foundation+1 more

Outrun Therapeutics is a preclinical biotech developing small molecule E3 ligase inhibitors to stabilise tumour suppressor proteins for treating cancer and other diseases.

BiotechDeep TechDundee, GB

Satpal Virdee(Founder)

Co-investorsM M VenturesDIDiamond Edge Ventures

PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address.

AI & Machine LearningBiotechDeep Tech

HSHannah Sore(Founder)in

Co-investorsCACambridge Angels groupMAMartlet CapitalDIDiamond Edge VenturesO2O2h VenturesPAParkwalk AdvisorsWRWren Capital

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

KEKevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)KRKasper Roet(Founder, Chief Executive Officer)inSVShafique Virani(Executive Officer)inJBJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Co-investorsALALS Investment FundDODolby Family VenturesDRDroia VenturesINInkefMIMission BiocapitalMIMitsui Global Investment+8 more

BiotechGreenville, US

KWKevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)

BoardMike Dial(Director)in

Co-investorsHAHatteras Venture PartnersILIllumina VenturesM M VenturesPAPappas CapitalSVSV Health InvestorsABAbbVie+2 more

SOLA Biosciences is a preclinical-stage biopharmaceutical company developing gene therapies for neurodegenerative diseases like ALS, Huntington's Disease, and Alzheimer's Disease by targeting misfolded proteins.

BiotechDeep TechMedical DevicesBoston, US

KKKeizo Koya(Founder and CEO)inAHAkinori Hishiya(Founder and CSF)in

Co-investorsEIEisai Innovation, Inc.UTUTEC

Sonde develops voice-based biomarker technology to detect health conditions early through analysis of speech patterns on everyday devices.

AI & Machine LearningDigital HealthHealthtech

DLDavid Liu(Chief Executive Officer)inJHJames Harper(Chief Strategy Officer)inYJYogendra Jain(Chief Technology Officer)inErik Larsen(Senior Vice President, Clinical Development & Customer Success)inSPSanjay Pothen(Chief Financial Officer)GBGarrett Bussiere(Vice President of Strategic Partnerships)in

Co-investorsEVEvidity Health CapitalM M Ventures

LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8.

BiotechDeep Tech

TKToru Kankein

Co-investorsTATaiho Ventures, LLCUTUTokyo Innovation Platform Co. Ltd.